ロード中...
Absence of complement component 3 does not prevent classical pathway–mediated hemolysis
Complement component 3 (C3) is emerging as a potential therapeutic target. We studied complement-mediated hemolysis using normal and C3-depleted human sera, wild-type (WT) and C3-deficient rat sera, and WT and C3 knockout rat models. In all of the in vitro and in vivo experiments, we found that the...
保存先:
| 出版年: | Blood Adv |
|---|---|
| 主要な著者: | , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
American Society of Hematology
2019
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6595256/ https://ncbi.nlm.nih.gov/pubmed/31196848 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2019031591 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|